Form 4: Acrivon Therapeutics Executive Sells Shares
Insider Transaction (Form 4)
Erick Gamelin, Chief Development Officer of Acrivon Therapeutics, Inc., sold 400 shares of common stock on August 18, 2026 for $2.01 per share.
Summary
- Open-market sale: disposed of 400 Common Stock at $2.01 ($804) on August 18, 2026; holds 52,592 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $804 of stock on the open market.
Insider Transactions
Erick Gamelin — Officer (Chief Development Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-18 | Open-market sale | Common Stock | 400 | $2 | $804 | 52,592 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-18 | Open-market sale (400 shares) |
Keywords
insider transaction, Form 4, ACRV, Acrivon Therapeutics, Inc., bearish, Erick Gamelin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.